iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings
Key Highlights
- ➤iMDx (IMDX) will participate in October 14 Kidney Health Forum discussions and investor meetings
- ➤KOL discussion features iMDx CEO Josh Riggs and transplant researcher Klemens Budde
- ➤GraftAssure dd-cfDNA technology monitored kidney transplant injury in a Phase 2 felzartamab study
- ➤Recent extension study used GraftAssure to guide felzartamab therapy
Expert Statements
Josh Riggs, CEO of Insight Molecular Diagnostics
“The potential for GraftAssure, including how localized, blood-based testing could help physicians assess treatment response, identify recurrence, and ultimately tailor anti-rejection therapy to individual patients”
Klemens Budde, Professor and senior physician at Charité – Universitätsmedizin Berlin
“The potential for GraftAssure, including how localized, blood-based testing could help physicians assess treatment response, identify recurrence, and ultimately tailor anti-rejection therapy to individual patients”
NASHVILLE, Tenn., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that on October 14, 2026, it will participate in the U.S. Bancorp I BTIG Kidney Health Forum, which will include a key opinion leader (KOL) virtual discussion and one-on-one meetings between investors and management.
The KOL discussion will feature iMDx CEO Josh Riggs, as well as Prof. Dr. Med. Klemens Budde, who is a kidney transplantation researcher and a head of the transplant program of the Department of Nephrology and Internal Intensive Care Medicine, at the Charité – Universitätsmedizin Berlin. Charité in Berlin is one of the world’s leading academic medical institutions, a European leader in transplantation, and the home of Germany’s largest kidney transplant program.
Get started
Create a free account to read the full story.